Filter search criteria using below inputs
Click on magnifying glass icon to search
Company | Country | Symbol |
---|
Time | Volume | NRXP |
---|---|---|
09:39 ET | 300 | 2.4 |
09:48 ET | 2100 | 2.45 |
09:54 ET | 100 | 2.5299 |
09:57 ET | 307 | 2.49 |
10:01 ET | 500 | 2.5 |
10:06 ET | 600 | 2.5 |
10:08 ET | 400 | 2.45 |
10:12 ET | 3269 | 2.435 |
10:28 ET | 1881 | 2.45 |
10:32 ET | 1130 | 2.5 |
10:33 ET | 1000 | 2.465 |
11:02 ET | 10500 | 2.4899 |
11:09 ET | 500 | 2.48 |
11:18 ET | 2101 | 2.5 |
12:02 ET | 1939 | 2.49 |
01:10 ET | 5254 | 2.48 |
01:15 ET | 4026 | 2.48 |
01:19 ET | 2500 | 2.505 |
01:33 ET | 200 | 2.48 |
01:46 ET | 250 | 2.53 |
01:48 ET | 19754 | 2.53 |
01:51 ET | 1000 | 2.5354 |
01:53 ET | 694 | 2.52 |
01:55 ET | 100 | 2.5349 |
02:04 ET | 198 | 2.525 |
02:06 ET | 6300 | 2.52 |
02:09 ET | 1000 | 2.51 |
02:11 ET | 100 | 2.51 |
02:13 ET | 100 | 2.53 |
02:15 ET | 4300 | 2.51 |
02:36 ET | 110 | 2.5104 |
02:42 ET | 100 | 2.525 |
02:58 ET | 1170 | 2.51 |
03:00 ET | 396 | 2.51 |
03:02 ET | 600 | 2.51 |
03:30 ET | 259 | 2.53 |
03:32 ET | 216 | 2.52 |
03:39 ET | 4843 | 2.53 |
03:41 ET | 3200 | 2.53 |
03:45 ET | 200 | 2.53 |
03:50 ET | 200 | 2.525 |
03:52 ET | 1800 | 2.515 |
03:56 ET | 821 | 2.515 |
03:57 ET | 476 | 2.5 |
03:59 ET | 1903 | 2.5 |
Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
---|---|---|---|
NRX Pharmaceuticals Inc | 26.8M | -1.2x | --- |
ALT5 Sigma Corp | 26.4M | -0.6x | --- |
Biora Therapeutics Inc | 26.2M | -0.1x | --- |
NeuroBo Pharmaceuticals Inc | 27.4M | -1.5x | --- |
BioVie Inc | 27.5M | -0.5x | --- |
UNITY Biotechnology Inc | 25.9M | -0.7x | --- |
NRX Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company. The Company is developing therapeutics based on its N-methyl-D-aspartate (NMDA) platform for the treatment of central nervous system disorders, specifically suicidal bipolar depression, chronic pain, and post-traumatic stress disorder (PTSD). The Company has two lead compounds, NRX-100, a proprietary presentation of ketamine and NRX-101, a fixed-dose combination of D-cycloserine (DCS) and lurasidone. The Company is developing NRX-101, a Food and Drug Administration (FDA)-designated investigational therapy for suicidal treatment-resistant bipolar depression and chronic pain. NRX-101 is a combined NMDA/5-HT2A-targeted medicine designed to address both depression and suicidal ideation, consisting of an oral, fixed dose combination of DCS and lurasidone. Its NRX-100 is racemic ketamine, which is a generic anesthetic. The Company is also engaged in the development of its new product, NRX-102.
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $26.8M |
---|---|
Revenue (TTM) | $0.00 |
Shares Outstanding | 10.7M |
Dividend Yield | 0.00% |
Annual Dividend Rate | --- |
Ex-Dividend Date | 01-01-01 |
Pay Date | 01-01-01 |
Beta | 1.26 |
EPS | $-2.06 |
Book Value | $-0.14 |
P/E Ratio | -1.2x |
Price/Sales (TTM) | --- |
Price/Cash Flow (TTM) | --- |
Operating Margin | --- |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.